Net Income

Match Group bets big on the future of dating, spinning out an AI venture while a new CEO steers Hinge toward its projected $1 billion revenue goal.

Ryman Hospitality's upcoming earnings call is a bellwether for conventions and country music. Here’s what investors are watching in its dual-engine strategy.

Amid LNG market fluctuations, Dynagas LNG Partners' new repurchase program signals deep financial health and a strategic play to boost unitholder value.

Beyond the headlines of a $592M debt reduction, McGraw Hill is executing a dual strategy: fortifying its finances to fund a digital and AI-driven future.

Nordson's record earnings reveal the high-tech backbone of premium goods and a resilient, behind-the-scenes investment in the high life.

The lab outfitter's Nu Aire acquisition fuels record revenue, but integration costs and market volatility paint a complex picture of strategic investment.

BridgeBio Oncology's new drug candidate BBO-10203 could redefine cancer therapy by avoiding a key toxicity, unlocking a vast market.

With a 2026 launch looming, Nuvalent adds a proven oncology dealmaker to its board, signaling a strategic pivot from R&D to market assault.

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.

How empowering 4,500 employees with $100 each transformed corporate giving, creating a wave of support for 2,100 charities nationwide.

A small biotech is challenging oncology's giants with a drug that targets cancer's core weakness, offering new hope to the sickest lung cancer patients.

How a bold $100M pandemic-era investment in a NYC landmark defied market gloom, achieving 100% occupancy and setting a new standard for office resilience.

Borr Drilling leverages complex debt and equity financing to acquire five premium rigs, a high-stakes bet on a strengthening offshore drilling market.

As climate disasters escalate, a major insurer is shifting from payouts to prevention. We decode this signal and its implications for the future of risk.

Lightbeam's new NCQA prevalidation isn't just a certificate. It's a strategic move reshaping compliance, patient outcomes, and the health tech market.

With a new $2B share buyback and strong dividends, Royal Caribbean isn't just recovering; it's setting a new course for shareholder value and growth.

With an early wallet launch and a key acquisition, Malaysia's Treasure Global is aiming for 100x growth. But can its hybrid strategy succeed?

The 2025 proxy season saw record director support as investors prioritized financials, yet dissent over executive pay signals a new battleground.

A struggling interactive entertainment firm bets its future on gold, targeting Malaysia's booming market. A look at the high-stakes pivot shaking up BHAT.

With a new patent, this biotech targets the massive orthopedics market. But can its novel fibroblast therapy overcome steep financial and clinical hurdles?